Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: A dose-ranging study

Journal of Lower Genital Tract Disease

Volumn 19, Issue 2, 2015, Pages 129-134

  Chavoustie, Steven E ^a   Jacobs, Mark ^b   Reisman, Howard A ^c   Waldbaum, Arthur S ^d   Levy, Sharon F ^e   Hillier, Sharon L ^f   Nyirjesy, Paul ^g  

^a Segal Institute for Clinical Research   (United States)

^b TMC Life Research Inc ^*  (United States)

^c PC   (United States)

^d Downtown Women's Health Care   (United States)

^e Prosoft Clinical   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bacterial; Gel; Metronidazole; Vaginosis

Indexed keywords

METRONIDAZOLE; AGENTS USED INTRAVAGINALLY; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTERIAL VAGINOSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FISHY ODOR; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA DISCHARGE; VAGINA DISEASE; VAGINAL BURNING SENSATION; VAGINAL PRURITUS; VULVA EDEMA; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; VAGINOSIS, BACTERIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; METRONIDAZOLE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 84925806896     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0000000000000062     Document Type: Article

References (11)

1. Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011;118:533-49.
2. Marrazzo JM. Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe 2011;17:186-90.
3. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007;109:114-20.
4. Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000;76:345-9.
5. Fethers KA, Fairley CK, Morton A, Hocking JS, Hopkins C, Kennedy LJ, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 2009;200:1662-70.
6. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis 2008;47:1426-35.
7. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55:1-94.
8. Brandt M, Abels C, May T, Lohmann K, Schmidts-Winkler I, Hoyme UB. Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur J Obstet Gynecol Reprod Biol 2008;141:158-62.
9. Livengood CH III, Soper DE, Sheehan KL, Fenner DE, Martens MG, Nelson AL, et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999;26:137-42.
10. Soper DE, Livengood C, Sheehan KL, Fenner DE, Martens MG, Nelson AL, et al. Safety and efficacy comparison of two dosing regimens of MetroGel-Vaginal(R) in the treatment of bacterial vaginosis: a multicenter, randomized, single-blind, parallel comparison. Prim Care Update Ob Gyns 1998;5:150.
11. Livengood CH III, Ferris DG, Wiesenfeld HC, Hillier SL, Soper DE, Nyirjesy P, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomised controlled trial. Obstet Gynecol 2007;110 (2 Pt 1):302-9.